BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021 Updated April 29, 2021 07:46pm
By

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed for this article.